AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03870321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core training
Description: In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise.
Study NCT03419468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Geriatric Assessment Measure (SGAM)
Description: Self Geriatric Assessment Measure
Study NCT03419468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self Geriatric Assessment Measure (SGAM)
Description: Self Geriatric Assessment Measure
Study NCT03893708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal yoga
Description: The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
Study NCT03893708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy education
Description: Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
Study NCT03734094 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic barrier
Description: The use of a ceramic barrier to induce bone formation during GBR
Study NCT03734094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium Mesh
Description: The use of a titanium mesh to induce bone formation during GBR
Study NCT04267575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Canady Helios Cold Plasma Scalpel
Description: Device used to distribute cold plasma energy at the resected tumor margins.
Study NCT01049074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture Treatment
Description: Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
Study NCT01049074 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
Study NCT02032667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-player condition
Description: Children in the multi-player condition will be able to play with and compete against other children in real time.
Study NCT01272986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALOA IgG-Elisa
Description: measurement of IgG Level in blood
Study NCT02615353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: 6-months of lifestyle education
Study NCT02615353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Control
Description: Medical visit and dietary counseling
Study NCT00588224 — intervention group
Intervention type: OTHER
Intervention: 3D ultrasound
Description: measurement of stomach volume by 3D ultrasound
Study NCT01272986 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ALOA IgG-Elisa
Description: measurement of IgG Level in blood
Study NCT01272986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ALOA IgG-AtheroAbzyme
Description: measurement of IgG in blood
Study NCT01449487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPC-5650
Description: Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
Study NCT01449487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for administration in the rectum Identical tp active solution but without active drug
Study NCT00395382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: 70mg weekly orally
Study NCT00395382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: weekly orally
Study NCT03073447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Specific blood sample of women under 50 years with acute MI
Description: The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
Study NCT00902967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg, once a day dosing at night after meals
Study NCT01272986 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ALOA IgG-AtheroAbzyme
Description: measurement of IgG in blood
Study NCT00902967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets of similar shape size and color given once a day at night time after meals
Study NCT00309179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820 plus cetuximab
Description: Escalating doses from 40 mg/m\^2 irinotecan plus E7820 in combination with cetuximab.
Study NCT00652041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
Study NCT00652041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is \<Grade 2, dose should be increased to 200 mg/24 h. in day 15
Study NCT00652041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
Study NCT01986491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid Y
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Study NCT01501422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen patch
Description: 50 microgram estrogen patch weekly
Study NCT01501422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo patch for 8 weeks
Study NCT02501135 — intervention group
Intervention type: PROCEDURE
Intervention: Femoral nerve block with ropivacaine or bupivacaine
Study NCT01495247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: Doses of oral BEZ235 (BID), supplied as 50mg, 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
Study NCT01495247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts.
Study NCT01246323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with Fentanyl+ Morphine
Description: Fentanyl 15 microgram Morphine 0.1-0.5 mg
Study NCT01650376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
Study NCT01650376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
Study NCT00967018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Study NCT01650376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
Study NCT02779296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-Octyl Cyanoacrylate Glue
Description: topical
Study NCT03393572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25%
Description: Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
Study NCT03393572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate.
Description: Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
Study NCT03393572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalbuphine
Description: Patients will receive intraperitoneal 5 mg nalbuphine
Study NCT02596087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem List Suggestion
Description: Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
Study NCT02184156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion
Study NCT02184156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL injection of Placebo
Study NCT00874133 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment for 12 weeks.
Study NCT00874133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motilium
Description: 20 mg motilium thrice daily
Study NCT04552093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Administration of intra-arterial floxuridine via the HAIP (HAIP chemotherapy) to the liver with concomitant Dutch standard of care systemic FOLFOX (5-FU, leucovorin and oxaliplatin) or FOLFIRI (5-FU, leucovorin and irinotecan).
Study NCT04552093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricumed IP2000V infusion pump
Description: Surgical implantation of hepatic artery infusion pump (HAIP) followed by administration of the combined chemotherapy (HAIP and systemic).
Study NCT02719795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local injection of local anesthetic into the fascial spaces
Study NCT02719795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
Study NCT00925782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection
Description: Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
Study NCT01986491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid X
Description: Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
Study NCT01986491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 120 mg solid Y
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Study NCT01986491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solution
Description: Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
Study NCT01867164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynoclin V
Description: One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
Study NCT01867164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vagitrol V
Description: One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
Study NCT00440518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
Study NCT00440518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
Study NCT00440518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
Study NCT01177020 — intervention group
Intervention type: OTHER
Intervention: Biological specimen
Description: Biological specimen taken from placenta
Study NCT05640531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 771 IV Infusion
Description: subjects will receive intravenous infusion of WCK 771
Study NCT05640531 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV Infusion
Description: subjects will receive matching placebo intravenous infusion
Study NCT04476160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon
Description: children recipe 3 grams by day of cinnamon
Study NCT00925782 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Description: Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
Study NCT02298205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma controller medication (Beclomethasone) adjustment strategy
Description: The participant will adjust the dose of Beclomethasone based on symptoms
Study NCT02298205 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Provider-based adjustment
Description: The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
Study NCT01652820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day
Study NCT03237754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS device from neuroConn
Description: weak electrical direct current stimulation
Study NCT03237754 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS device from neuroConn
Description: weak electrical direct current stimulation
Study NCT03003468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
Study NCT03003468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200mg IV
Study NCT03003468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
Study NCT03436927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Balance exercises
Description: Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
Study NCT03436927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Trainer Balance Exercises
Description: Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
Study NCT03752827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose Derived Regenerative Cells
Description: Adipose-derived regenerative cells isolated with the Transpose Ultra system
Study NCT03752827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Corticosteroid injection into subacrominal space
Study NCT02957643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron
Description: oral treatment
Study NCT02957643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: oral treatment
Study NCT04079959 — intervention group
Intervention type: PROCEDURE
Intervention: endometrial biopsy
Description: . Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
Study NCT02520466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavanol-rich drink vs flavanol-free drink
Description: Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
Study NCT02520466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: flavanol-rich drink vs flavanol-free drink
Description: Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
Study NCT05788380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EXERCİSE
Description: EXERCISE FOR HEALTH AND PAIN IMPROVEMENT
Study NCT04682613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Prevention Program young In Favor of Myself, active teachers
Description: Prevention program: young In Favor of Myself, with teacher participation
Study NCT04682613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Prevention Program young In Favor of Myself, no teacher involvement
Description: Prevention program: young In Favor of Myself, without teacher participation
Study NCT04351815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short term prehabilitation (2 weeks)
Description: * Initial assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine) and a geriatrician (for patients over 75 years old)~* Patient will be asked to follow a 2 weeks prehabilitation program~* 2 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)~* 6 months post-surgery assessment visit with a dietitian, a psychologist, a physiotherapist, a doctor (physical medicine)
Study NCT01652820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d